NexMed, Inc., a specialty CRO with a pipeline of product candidates based on the NexACT technology, announced that the Japanese Patent Office has issued the Decision to Grant a Patent for NexMed’s patent application entitled, “Prostaglandin Compositions for the Treatment of Male Erectile Dysfunction.” This patent, when issued, will provide Japanese patent protection to September 2021 and is one in a series of patents and pending applications that NexMed owns on Vitaros® and the underlying NexACT technology.

Commenting on news, Dr Bassam Damaj, president and chief executive officer of NexMed, stated, “We are very pleased with our first patent allowance for Vitaros in Japan. Throughout its history, the Company has aggressively pursued intellectual property coverage for its technology and products under development. In addition to the newly allowed claims in Japan, we have corresponding coverage and protection for Vitaros in the major international markets.”